|1.||Dhalla, Naranjan S: 6 articles (10/2012 - 01/2002)|
|2.||Kumamoto, Hideo: 5 articles (09/2008 - 01/2002)|
|3.||Fujita, Masatoshi: 4 articles (04/2008 - 08/2002)|
|4.||Takeda, Nobuakira: 4 articles (04/2008 - 01/2002)|
|5.||Nishimaru, Katsuya: 3 articles (08/2009 - 01/2007)|
|6.||Sanganalmath, Santosh K: 3 articles (09/2008 - 01/2008)|
|7.||Barta, Judit: 3 articles (09/2008 - 01/2008)|
|8.||Tanaka, N: 3 articles (07/2008 - 11/2000)|
|9.||Kim, Sang-Hyun: 2 articles (07/2015 - 01/2010)|
|10.||Iizuka, Kenji: 2 articles (01/2013 - 01/2009)|
09/01/2006 - "The findings demonstrate that sustained-release bFGF stimulated the development of collateral vessels, and additional administration of sarpogrelate produced a further improvement in hindlimb blood flow in the rabbit hindlimb ischemia model."
01/01/2010 - "Sarpogrelate hydrochloride, a selective 5-hydroxytryptamine(2A) antagonist, augments autologous bone marrow mononuclear cell implantation-induced improvement in endothelium-dependent vasodilation in patients with critical limb ischemia."
02/01/2013 - "This study was designed to examine the impact of combined multipotent adipose-derived stromal cells (mADSCs) and sarpogrelate treatment on aging hindlimb ischemia and the mechanism of action involved. "
01/01/2010 - "The purpose of this study was to determine the effect of a combination of bone marrow mononuclear cell (BM-MNC) implantation and sarpogrelate, a selective 5-HT(2A) antagonist, on endothelial function in patients with critical limb ischemia (CLI). "
07/01/2014 - "Effect of sarpogrelate treatment on the prognosis after endovascular therapy for critical limb ischemia."
|2.||Systemic Scleroderma (Systemic Sclerosis)
02/01/2006 - "Sarpogrelate hydrochloride (SH) is an antagonist of the 5-hydroxytryptamine2A (5HT2A) receptor and has been reported to be effective in the treatment of systemic sclerosis (SSc) patients with Raynaud phenomenon. "
06/01/2012 - "Eleven patients with skin ulcers and systemic sclerosis (SSc) were administrated sarpogrelate p.o. "
06/01/2012 - "Effects of sarpogrelate hydrochloride on skin ulcers and quality of life in patients with systemic sclerosis."
11/01/2000 - "We evaluated the effect of 12 months of 300-mg oral sarpogrelate hydrochloride (SH) once daily on the symptoms of Raynaud's phenomenon, respiratory failure and cardiac function in seven patients with systemic sclerosis. "
11/01/2000 - "Suppressive effect of sarpogrelate hydrochloride on respiratory failure and right ventricular failure with pulmonary hypertension in patients with systemic sclerosis."
02/01/2007 - "However, the efficacy of sarpogrelate for pain relief in this situation has not been established by clinical studies and its mechanism remains unknown. "
02/01/2007 - "Although further investigation is needed concerning the mechanism of action, this study supported the hypothesis that sarpogrelate is efficacious for treating the pain of lumbar disc herniation."
02/01/2007 - "Sarpogrelate attenuated pain-related behavior induced by the nucleus pulposus in the animal model. "
02/01/2007 - "To evaluate the effects of sarpogrelate hydrochloride on neurogenic pain induced by nucleus pulposus translocation and to elucidate its mechanism. "
05/23/2005 - "In conclusion, sarpogrelate might be analgesic on inflammatory induced acute and facilitated pain by intrathecal or systemic administration. "
05/01/1999 - "5. In protocol II, in the sarpogrelate treatment group (group E), albuminuria was significantly improved and both plasma levels TXB2 and urinary TXB2 excretion were significantly decreased. "
03/01/2008 - "Sarpogrelate has been shown to reduce albuminuria in diabetic nephropathy. "
11/01/2002 - "Sarpogrelate hydrochloride, a serotonin2A receptor antagonist, reduces albuminuria in diabetic patients with early-stage diabetic nephropathy."
04/01/2008 - "Treatment with sarpogrelate improved ROS/NO imbalance in glomeruli, suppressed platelet aggregation in glomeruli, reduced platelet-derived microparticles, increased serum adiponectin level and reduced the level of albuminuria, compared with non-treated diabetic rats. "
03/01/2008 - "Reduced albuminuria with sarpogrelate is accompanied by a decrease in monocyte chemoattractant protein-1 levels in type 2 diabetes."
|5.||Collagen Diseases (Collagen Disease)
06/01/2012 - "Sarpogrelate hydrochloride (sarpogrelate) is a selective 5-HT(2A) antagonist and was supposed to be effective for Raynaud's phenomenon with collagen disease. "
06/01/1998 - "To evaluate clinical efficacy of sarpogrelate hydrochloride (SPG), a novel 5HT2- serotonergic receptor antagonist, for Raynaud's phenomenon associated with collagen diseases. "
06/01/1998 - "[Sarpogrelate hydrochloride for Raynaud's phenomenon of patients with collagen diseases]."
06/01/2012 - "Sarpogrelate has not been investigated regarding the effects, safety and quality of life (QOL) in patient with skin ulcers of collagen disease. "
10/01/2000 - "Twenty-seven patients with either collagen disease or diseases associated with Raynaud's phenomenon were given a combined 5-HT2 and serotonin receptor antagonist, sarpogrelate hydrochloride. "
|1.||Serotonin (5 Hydroxytryptamine)
|2.||5-HT2A Serotonin Receptor (5 HT2A Receptor)
|6.||Serotonin 5-HT2 Receptor Antagonists
|7.||Platelet Aggregation Inhibitors (Antiplatelet Drugs)
|8.||Type 3 Cyclic Nucleotide Phosphodiesterases
|10.||Caspase 3 (Caspase-3)
|1.||Heart Valve Prosthesis
|5.||Homologous Transplantation (Allograft)